Scientific Evidence and Financial Obligations to Ensure Access to Biosimilars for Cancer Treatment

JAMA. 2017 Jan 3;317(1):33-34. doi: 10.1001/jama.2016.18743.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Biosimilar Pharmaceuticals / therapeutic use*
  • Drug Approval*
  • Humans
  • Neoplasms / drug therapy
  • United States Food and Drug Administration

Substances

  • Biosimilar Pharmaceuticals